Skip to main content

Select Drug Profiles

GU Cancers Symposium Highlights

Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer

GU Cancers Symposium Highlights

Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Interview with the Innovators

Genmab Is Ready to Enter the US Market to Help Improve the Lives of People with Cancer

Ron Graybill, Brad Bailey

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation

Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer

Interview with the Innovators

Introducing Genmab-Rooted in Science and Inspired by Patients to Transform the Future of Cancer Treatment

Anthony Mancini, Ron Graybill

Page 16 of 244
Results 151 - 160 of 2438